Coya Therapeutics reports FY2022 net loss of $12.2M; positive ALS data for COYA 302

Coya Therapeutics, Inc.

Net loss of $12.2M for FY2022 vs $4.9M in FY2021; R&D expense rose to $4.4M from $2.5M.
Cash and cash equivalents $5.9M at Dec 31, 2022; IPO net proceeds of $14.5M received in Jan 2023.
Positive proof-of-concept data for COYA 302 in ALS: halted disease progression over 6 months in 4 patients.
Entered worldwide agreement with Dr. Reddy's to in-license abatacept biosimilar and out-license COYA 301.
Anticipates IND filing for COYA 301 in FTD and COYA 302 in neurodegenerative diseases in H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Coya Therapeutics, Inc. reported fiscal year ended December 31, 2022 results: net income $12.2 million.

Period: fiscal year ended December 31, 2022
Net income: $12.2 million
Result: reported results

Exact text from the filing

On March 29, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010589

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.